)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Revance Therapeutics
Revance Therapeutics (RVNC) investor relations material
Revance Therapeutics has been acquired
Revance Therapeutics Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary7 Nov, 2024
Executive summary
Q3 2024 revenue was $59.9 million, up 11% year-over-year, driven by increased DAXXIFY and RHA® Collection sales.
Net loss from continuing operations for Q3 2024 was $38.1 million, compared to $39.4 million in Q3 2023; total net loss including discontinued operations was $141.2 million.
The company completed the exit of its Fintech Platform business, now classified as discontinued operations, resulting in $101.7 million in Q3 2024 net loss from discontinued operations.
A pending merger with Crown Laboratories is in process, with a tender offer at $6.66 per share; the deadline was extended to November 12, 2024, and closing is subject to customary conditions.
Management has concluded there is substantial doubt about the company's ability to continue as a going concern due to insufficient liquidity to fund operations for 12 months.
Financial highlights
Q3 2024 product revenue: $58.8 million (up 9% year-over-year); nine-month product revenue: $175.9 million (up 14%).
DAXXIFY Q3 2024 revenue: $28.3 million (up 29%); RHA® Collection Q3 2024 revenue: $30.5 million (down 5%).
Operating expenses for Q3 2024 were $92.1 million, flat year-over-year; SG&A expenses were $62.6 million, down from $65.8 million, including $7.3 million in merger-related costs.
Cash, cash equivalents, and short-term investments as of September 30, 2024: $184.1 million, down from $253.9 million at year-end 2023.
Net loss per share from continuing operations for Q3 2024 was $0.37; total net loss per share was $1.63.
Outlook and guidance
Management expects continued operating losses and negative cash flows for the foreseeable future.
Existing cash and investments are not sufficient to fund operations for at least 12 months; additional financing or cost reductions may be required.
All previously provided 2024 financial guidance was withdrawn and no forward-looking outlook will be provided due to the proposed merger.
The pending merger with Crown Laboratories, if completed, will result in the company becoming a wholly owned subsidiary and delisting from Nasdaq.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Revance Therapeutics
- Q2 revenue up 20% to $65.4M, DAXXIFY and RHA drive growth, 2024 revenue guidance at $280M+.RVNC
Q2 2024 - DAXXIFY's relaunch drives market share gains and strong growth, with positive EBITDA expected in 2025.RVNCThe 44th Annual William Blair Growth Stock Conference
- DAXXIFY and RHA fillers drive growth as global expansion and therapeutics gain momentum.RVNCGoldman Sachs 45th Annual Global Healthcare Conference
Revance Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Revance Therapeutics Inc. is a biotechnology company focused on developing and commercializing innovative aesthetic and therapeutic treatments. The company’s portfolio includes Daxxify, a long-lasting botulinum toxin for wrinkle reduction, and other injectable products for aesthetic enhancements. Revance also develops treatments targeting neurological and musculoskeletal disorders. Revance Therapeutics is headquartered in Nashville, Tennessee, and its shares are listed on the NASDAQ.